Pharvaris (PHVS) said Thursday it now expects to release in Q4 the topline data from the ongoing phase 3 trial assessing deucrictibant immediate-release capsule for the on-demand treatment of hereditary angioedema, or HAE, attacks.

Pending positive data, a new drug application is expected to be submitted with the US Food and Drug Administration in H1 of 2026, the company said.

The updated timing is a pull-forward of about one quarter from the previous timing guidance, Wedbush Securities said in a note Thursday.

"We... continue to see [Pharvaris] as uniquely positioned in the HAE space with deucrictibant offering benefit in both the acute and prophylactic settings," the firm said.

Wedbush maintained the company's outperform rating and $27 price target.